|1.||Nakagawa, Tsutomu: 6 articles (06/2009 - 11/2005)|
|2.||Sugaru, Eiji: 6 articles (06/2009 - 11/2005)|
|3.||Tokunaga, Teruhisa: 6 articles (06/2009 - 11/2005)|
|4.||Taiji, Mutsuo: 6 articles (06/2009 - 11/2005)|
|5.||Kitoh, Makoto: 6 articles (06/2009 - 11/2005)|
|6.||Nagata, Ryu: 6 articles (06/2009 - 11/2005)|
|7.||Nagamine, Jun: 5 articles (06/2009 - 01/2006)|
|8.||Ono-Kishino, Michiko: 5 articles (06/2009 - 01/2006)|
|9.||Hume, W Ewan: 4 articles (01/2007 - 11/2005)|
|10.||Tsujimura, Tsuyoshi: 2 articles (06/2009 - 01/2008)|
04/01/2006 - "SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice."
06/01/2009 - "We have previously reported that the anti-fibrotic agent SMP-534 has beneficial effects on renal fibrosis in animal model of nephropathy. "
01/01/2008 - "Additionally, SMP-534 inhibits glomerular fibrosis and provides renoprotection in vivo. "
01/01/2006 - "SMP-534 significantly suppressed an increase in urinary albumin excretion and ameliorated the progression of glomerular fibrosis in db/db mice, whereas losartan did not. "
01/01/2006 - "We examined the effects of combined treatment with SMP-534 and losartan on urinary albumin and glomerular fibrosis in db/db mice. "
|2.||Diabetic Nephropathies (Diabetic Nephropathy)
04/01/2006 - "Hence, antifibrotic agents such as SMP-534 might be a new therapeutic option for the treatment of diabetic nephropathy."
01/01/2007 - "The study results indicate that a combination of SMP-534 and losartan might be a valuable therapeutic approach for the treatment of diabetic nephropathy even when administration is started after the onset of diabetic nephropathy."
01/01/2007 - "SMP-534 or losartan was prophylactically administered to db/db mice before the onset of diabetic nephropathy. "
01/01/2007 - "Amelioration of established diabetic nephropathy by combined treatment with SMP-534 (antifibrotic agent) and losartan in db/db mice."
01/01/2006 - "A combination of the two agents, SMP-534 and losartan, might be a valuable therapeutic approach for the treatment of diabetic nephropathy."
|3.||Renal Insufficiency (Renal Failure)
04/01/2006 - "In this study, we examined the long-term effects of SMP-534 on renal insufficiency and glomerulosclerosis in db/db mice, which are models of type 2 diabetes. "
01/01/2008 - "Five groups of rats were studied: sham operated, 5/6Nx + vehicle, 5/6Nx + SMP-534 30 mg/kg, 5/6Nx + SMP-534 60 mg/kg and 5/6Nx + SMP-534 90 mg/kg. Treatment with SMP-534 began 13 weeks after surgery, when hypertension and renal insufficiency had developed. "
|4.||Pulmonary Fibrosis (Hamman Rich Syndrome)
06/01/2009 - "The results of this study indicate that the anti-fibrotic agent SMP-534 may offer a new therapeutic option for the treatment of pulmonary fibrosis."
06/01/2009 - "In this study, we examined whether SMP-534 has beneficial effects on pulmonary fibrosis in bleomycin-treated hamsters. "
06/01/2009 - "The anti-fibrotic agent SMP-534 attenuates bleomycin-induced pulmonary fibrosis in hamsters."
|3.||Transforming Growth Factor beta (TGF-beta)
|4.||Angiotensin Receptor Antagonists
|5.||Plasminogen Activator Inhibitor 1
|6.||Advanced Glycosylation End Products
|7.||Transforming Growth Factors (Transforming Growth Factor)
|8.||RNA (Ribonucleic Acid)